Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Date:6/4/2009

tical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's clinical development programs. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking st
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two June Healthcare Conferences
2. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
3. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
4. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
5. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
9. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
10. ViroPharma to Present at Three October Healthcare Conferences
11. ViroPharma to Present at Three September Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 2014 Not long ago, it was ... be performed late in the development cycle – even ... regulatory trends suggest that, like many things GxP, expectations ... recent years, multiple drug sponsors have been required by ... questions during phase I/II. It’s not only clinical trial ...
(Date:8/20/2014)... 2014 GraphDB™ 6.0 ... improvements to the enterprise replication cluster, faster loading ... SOLR and Elasticsearch. This release happens to coincide ... triplestore – GraphDB™ was formerly known as OWLIM. ... only mature enterprise resilient RDF triplestore will also ...
(Date:8/19/2014)... 2014 A Geisinger researcher on a personal ... Centers for Disease Control and Prevention (CDC) award recognizing ... concern. Joseph Boscarino , Ph.D. MPH, ... team of researchers nominated for the Centers for Disease ... for Data Methods and Study Design. "Hepatitis ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... , ... WX ), a,leading pharmaceutical, biotechnology, and medical-device research ... United States,announced that it had been selected to the ... consecutive year. The list recognizes the 50,fastest-growing companies in ...
... , DURHAM, N.C., Nov. 27 ... water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. ... walls that allows for conjugation with cancer drugs, was developed ... conjugated carbon nanotubes serves as a drug delivery vehicle with ...
... , BOSTON, Nov. 25 Biotech firm Replikins Ltd., ... pandemic through the prediction, outbreak, and progress of the current H1N1 ... new data shows that the lethality of the H1N1 ("Swine Flu") ... the virus,s current outbreak in the spring of 2009 to resting ...
Cached Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... release is available in German . ... been awarded this year,s Heinz Maier-Leibnitz Prizes. The relevant ... Germany,s most prestigious award for young scientists. The prizewinners ... Hanover, Dr. Wilhelm Hofmann, Psychology, University of Wrzburg, Dr. ...
... triggered by environmental stimuli and often occur in response to ... predisposition to develop these diseases, which highlights a role for ... high number of people with depression have a genetic change ... each other in the brain. Imaging of people with ...
... Williams boards ferries bound for North Carolina,s Outer Banks, the ... her the "Pollen Lady." Each spring from 2006 ... to the mainland, collecting pine pollen blown far offshore. She ... the most commonly planted tree in the southern United ...
Cached Biology News:Heinz Maier-Leibnitz Prizes 2010: 6 outstanding young researchers honored 2Heinz Maier-Leibnitz Prizes 2010: 6 outstanding young researchers honored 3Heinz Maier-Leibnitz Prizes 2010: 6 outstanding young researchers honored 4Depression associated with sustained brain signals 2Gone with the wind: Far-flung pine pollen still potent miles from the tree 2
... isolated fromStreptomyces griseolusthat inhibits protein synthesis. ... in eukaryote ribosomes. Reported to induce ... including promyelocytic leukemia cells, Jurkat cells, ... Initiates intracellular signals and immediate early ...
... RC DC protein assay kit I provides reagents ... in the presence of reducing agents and detergents. ... assay. The kit includes reagents and standards sufficient ... I, 250 ml RC reagent II, 250 ml ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Biology Products: